[{"id":"f8bfbabd-a095-4dce-9f97-609ef1a78c91","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225584","created_at":"2022-11-09T15:57:03.257Z","updated_at":"2024-07-02T16:35:41.087Z","phase":"Phase 1","brief_title":"Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors","source_id_and_acronym":"NCT05225584","lead_sponsor":"Kymera Therapeutics, Inc.","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KT-333"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/19/2022","start_date":" 05/19/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-08-03"}]